K-V Pharmaceutical announced Friday, that in view of the unusual market activity in the Company's common stock, the NYSE has contacted the Company in accordance with its usual practice. K-V's policy is not to comment on unusual market activity.

Uroplasty announced Thursday two new research and development initiatives to expand its commitment to using the Company's neuromodulation technology to treat voiding dysfunctions.

The development project, based on a patent the Company holds, of an implantable tibial nerve stimulator for the treatment of OAB is focused on securing a CE Mark for the European market. The Company expects the success of its Urgent PC Neuromodulation System, which delivers percutaneous tibial nerve stimulation by the temporary insertion of a needle electrode, will provide insight into the design and clinical elements of an implantable device. The implantable device will allow patients who initially respond to Urgent PC therapy administered in the doctor's office, to continue self-administering the therapy in the comfort of their homes.

Trading in China Shen Zhou Mining was halted on a circuit breaker on Friday, following a sharp spike in volume. A spokesperson for the company told Benzinga there was no news to account for the spike and he attributed the move to "normal market activity".

China Shen Zhou Mining closed at $1.03 on Friday.

The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment.
Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.